In re Solodyn Antitrust Litig., No. 14-10438 (D. Mass.)

In the Solodyn case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Medicis’s minocycline drug, Solodyn.  The case alleges that Medicis engaged in an anticompetitive scheme to prevent lower-priced generic competition from entering the market.  The scheme included product reformulations to prevent pharmacists from substituting less-expensive generic versions of Solodyn, and pay-for-delay conspiracies between Medicis and would-be generic competitors. The case settled for $75 million in early 2018.